Health and population

Health and population dynamics are intertwined, embodying an intricate relationship with significant implications on the Sustainable Development Goals (SDGs). Health is fundamentally at the center of these 17 global goals, aimed to transform the world by 2030. Specifically, Goal 3 endeavors to "Ensure healthy lives and promote well-being for all at all ages." It acknowledges that health is pivotal to human life quality, social cohesion, and sustainable development. Inextricably linked to this are the complexities of population dynamics, including growth rates, age structure, fertility and mortality rates, and migration patterns.

With the world's population projected to exceed 9.7 billion by 2050, the pressure on health systems will undoubtedly escalate. The demographic transition, with an aging population and an increasing prevalence of non-communicable diseases, poses new challenges for health systems globally. Additionally, areas with high fertility rates often overlap with extreme poverty, resulting in heightened health risks, including higher maternal and child mortality rates, malnutrition, and infectious diseases.

Moreover, rapid urbanization and migration present both opportunities and threats to health. While urban areas may provide better access to healthcare, they also harbor risks of disease transmission, air and water pollution, and social determinants of health like inadequate housing and social inequality. Simultaneously, migrants often face disproportionate health risks due to unstable living conditions, exploitation, and limited access to healthcare services.

Achieving the SDGs will necessitate comprehensive approaches that consider the intricate interplay of health and population dynamics. It means strengthening health systems, promoting universal health coverage, and addressing social determinants of health. It also implies crafting policies that recognize demographic realities and foster an environment conducive to sustainable development. Only by understanding and harnessing these dynamics can the world meaningfully progress towards realizing the SDGs, ensuring healthy lives and well-being for all.

The article describes the development of a self-regulated multi-functional nano-modulator (siR/PIO@RP) that can intelligently navigate to the damaged blood-brain barrier and release therapeutic cargoes for synergetic Alzheimer's disease (AD) therapy. The nano-modulator is capable of reducing cerebral amyloid-β load, relieving neuroinflammation, and alleviating the dysfunction of the neurovascular unit, providing proof of concept that normalizing the neurovascular unit holds promise as a means of alleviating AD symptoms.
The article explores the associations between three healthy dietary patterns (DASH, aMED, and HDS) and homeostatic dysregulation (HD), a measure of aging-related physiological dysregulation, in a large prospective cohort from less-developed ethnic minority regions in China.
Elsevier,

Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Advances, 2025, pp 3-15

This content aligns with Goal 3: Good Health and Wellbeing and Goal 9: Industry, Innovation, and Infrastructure by discussing the roles of Tau, glial, and amyloid (A) in Alzheimer's Disease development.

Rare Disease Education:  Alpha-1 Antitrypsin Deficiency

Editor: Kelsey LaFayette, DNP, RN, FNP-C

Rare Disease Education:  Myasthenia Gravis

Editor: Kelsey LaFayette, DNP, RN, FNP-C

Rare Disease Education:  Acoustic Neuroma

Editor: Kelsey LaFayette, DNP, RN, FNP-C

Rare Disease Education:  Necrotizing Enterocolitis

Editor: Kelsey LaFayette, DNP, RN, FNP-C

Rare Disease Education:  Von Hippel-Lindau Disease

Editor: Kelsey LaFayette, DNP, RN, FNP-C

This cross-sectional population-based study examined the relationship between statin use and anti-Alzheimer's disease (AD) drug prescription in patients over 70 years old with cardiovascular risk factors. The key findings were: 1) Patients using low-potency or hydrophilic statins had lower odds of anti-AD medication usage compared to high-potency or lipophilic statins, respectively; 2) Patients taking rosuvastatin or pitavastatin had lower odds of anti-AD medication usage than those consuming atorvastatin.
The article discusses the connection between type 2 diabetes mellitus (T2DM) and neurodegenerative disorders, with a focus on the role of mitochondrial dysfunction as a potential link between these conditions. It reviews the epidemiological and molecular evidence that suggests T2DM as a risk factor for the development of Alzheimer's disease and Parkinson's disease, and highlights the importance of understanding the mitochondrial mechanisms underlying this relationship to identify new therapeutic targets.

Pages